Company / Shareholders' Equity
Cardiff Oncology, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$45.4M
FY2025
5-year range
$45.4M / $140.4M
FY2021-FY2025
Trend
-34.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $140M in FY2022 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of -18.7%.
Declined from $106M to $45M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -31.4%
- 5-Year CAGR
- -18.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Cardiff Oncology, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of -18.7%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 34.9% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.4M | -34.9% |
| FY2024 | $69.7M | -34.4% |
| FY2023 | $106.3M | -24.3% |
| FY2022 | $140.4M | +9.6% |
| FY2021 | $128.2M | +0.0% |
| FY2020 | $128.2M | +1652.7% |
| FY2019 | $7.3M | +12.4% |
| FY2018 | $6.5M | -67.1% |
| FY2017 | $19.8M | -59.4% |
| FY2016 | $48.7M | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026